A5050487104- Respiratory viral infections research
- Influenza Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Pneumonia and Respiratory Infections
- Viral gastroenteritis research and epidemiology
- Bacterial Infections and Vaccines
- SARS-CoV-2 detection and testing
- Blood donation and transfusion practices
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Hepatitis B Virus Studies
- Mosquito-borne diseases and control
- Mycobacterium research and diagnosis
- Viral Infections and Vectors
- COVID-19 Impact on Reproduction
- Hepatitis C virus research
- Animal Virus Infections Studies
- Infective Endocarditis Diagnosis and Management
- Animal Disease Management and Epidemiology
- Tuberculosis Research and Epidemiology
- Reproductive tract infections research
- Viral Infections and Immunology Research
- Syphilis Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
Canadian Blood Services
2019-2025
University of Alberta
2016-2025
Centre for Global Health Research
2023
McGill University Health Centre
2017-2023
University of Saskatchewan
2023
Saskatchewan Health Authority
2023
Saskatchewan Health
2023
Provincial Laboratory of Public Health
2012-2021
Alberta Health Services
2012-2019
University of Alberta Hospital
2014-2019
While the antibody response to SARS-CoV-2 has been extensively studied in blood, relatively little is known about saliva and its relationship systemic levels. Here, we profiled by enzyme-linked immunosorbent assays (ELISAs) IgG, IgA IgM responses spike protein (full length trimer) receptor-binding domain (RBD) serum of acute convalescent patients with laboratory-diagnosed COVID-19 ranging from 3-115 days post-symptom onset (PSO), compared negative controls. Anti-SARS-CoV-2 were readily...
In three case-control studies and a household transmission cohort, Danuta Skowronski colleagues find an association between prior seasonal flu vaccination increased risk of 2009 pandemic H1N1 flu.
Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a humoral immune response to virus within few weeks infection, but duration this and how it correlates clinical outcomes has not been completely characterized. Of particular importance is identification infection that would support public health decision-making on treatment approaches, vaccination strategies, convalescent plasma therapy. While ELISA-based assays detect quantitate antibodies...
Background. The 2014–2015 influenza season was distinguished by an epidemic of antigenically-drifted A(H3N2) viruses and vaccine components identical to 2013–2014. We report effectiveness (VE) from Canada explore contributing agent–host factors. Methods. VE against laboratory-confirmed derived using a test-negative design among outpatients with influenza-like illness. Sequencing identified amino acid mutations at key antigenic sites the viral hemagglutinin protein. Results. Overall, 815/1930...
Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune responses. Here, we describe a scalable solution to detect quantify SARS-CoV-2 antibodies, discriminate between natural infection- vaccination-induced responses, assess antibody-mediated inhibition of the spike-angiotensin converting enzyme (ACE2) interaction.
To date, no study has examined influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza-associated hospitalizations during pregnancy. The Pregnancy Influenza Vaccine Effectiveness Network (PREVENT) consisted of public health or healthcare systems with integrated laboratory, medical, and vaccination records in Australia, Canada (Alberta Ontario), Israel, the United States (California, Oregon, Washington). Sites identified pregnant women aged 18 through 50 years whose...
The antigenic distance hypothesis (ADH) predicts that negative interference from prior season's influenza vaccine (v1) on the current (v2) protection may occur when is small between v1 and v2 (v1 ≈ v2) but large epidemic (e) strain ≠ e). Vaccine effectiveness (VE) against medically attended, laboratory-confirmed A(H3N2) illness was estimated by test-negative design during 3 epidemics (2010–2011, 2012–2013, 2014–2015) in Canada. derived with covariate adjustment across and/or categories...
<h3>Background:</h3> A resurgence of pertussis cases among both vaccinated and unvaccinated people raises questions about vaccine effectiveness over time. Our objective was to study the characterize effect waning immunity whole-cell priming. <h3>Methods:</h3> We used test-negative design, a nested case–control with individuals as controls. constructed multivariable logistic regression models estimate odds ratios (ORs). Vaccine calculated (1 – OR) × 100. assessed by calculating developing per...
Binary file ES_Abstracts_Final_ECDC.txt matches
Chlamydia trachomatis is the most common notifiable disease in Canada, and extragenital sites are believed to serve as hidden reservoirs for ongoing transmission of infection. There no specific Canadian screening guidelines asymptomatic individuals from sites. We sought determine prevalence factors associated with rectal C. among female sexually transmitted infection (STI) clinic attendees Alberta, Canada.Between 20 July 31 December 2012, all at 2 Provincial STI clinics receiving a pelvic...
Vaccine effectiveness (VE) estimates for 2015-2016 seasonal influenza vaccine are reported from Canada's Sentinel Practitioner Surveillance Network (SPSN). This season was characterized by a delayed 2009 pandemic A(H1N1) virus (A[H1N1]pdm09) epidemic and concurrent B(Victoria) activity. Potential influences on VE beyond antigenic match explored, including viral genomic variation, birth cohort effects, prior vaccination, period.VE estimated test-negative design comparing the adjusted odds...
Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE A(H3N2), driven by predominant subgroup clade 3C.2a viruses with T131K + R142K R261Q substitutions, was low at 17% (95% confidence interval (CI): -14 to 40). B higher 55% CI: 38 68) despite prominent use trivalent containing lineage-mismatched B(Victoria) antigen, suggesting cross-lineage protection.
<h3>Background:</h3> During the first year of COVID-19 pandemic, proportion reported cases among Canadians was under 6%. Although high vaccine coverage achieved in Canada by fall 2021, Omicron variant caused unprecedented numbers infections, overwhelming testing capacity and making it difficult to quantify trajectory population immunity. <h3>Methods:</h3> Using a time-series approach data from more than 900 000 samples collected 7 research studies collaborating with Immunity Task Force...
Nucleic acid tests are sensitive and specific provide a rapid diagnosis, making them invaluable for patient outbreak management. Multiplex PCR assays have additional advantages in providing an economical comprehensive panel many common respiratory viruses. Previous reports shown the utility of xTAG viral (RVP) assay manufactured by Luminex Molecular Diagnostics this purpose. A newer generation kit, released Canada early 2010, is designed to simplify procedure reduce turnaround time about 24...
ObjectivesTo improve our understanding of the global epidemiology common respiratory viruses by analysing their contemporaneous incidence at multiple sites.Methods2010–2015 data for influenza A (IAV), B (IBV), syncytial (RSV) and parainfluenza (PIV) virus infections were collected from 18 sites (14 countries), consisting local (n = 6), regional 9) national 3) laboratories using molecular diagnostic methods. Each site submitted monthly data, together with details patient populations tested...
Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant A(H3N2) viruses considered antigenically matched to clade 3C.2a strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18–59%) overall, with variation province. Interim virological findings reported here warrant...
Abstract While the antibody response to SARS-CoV-2 has been extensively studied in blood, relatively little is known about mucosal immune and its relationship systemic levels. Since initially replicates upper airway, oral cavity likely an important parameter that influences course of infection, but how it correlates serum not known. Here, we profile by enzyme linked immunosorbent assays (ELISAs) IgG, IgA IgM responses spike protein (full length trimer) receptor binding domain (RBD) (n=496)...
Abstract Background Case detection underestimates the burden of COVID‐19 pandemic. Following first wave, we estimated seroprevalence severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) among blood donors across Canada. Study Design and Methods This serial cross‐sectional study was conducted between May 9 July 21, 2020 from donating at all Canadian Blood Services locations. We used Abbott Architect assay to detect SARS‐CoV‐2 IgG antibodies retention plasma. Seroprevalence...